Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly. This includes the induction of molecular markers associated with senescence, a form of cellular aging that typically involves growth arrest. We have shown that VEGFR TKIs can hijack these aging programs by transiently inducting senescence markers (SMs) in tumor cells to activate senescence-associated secretory programs that fuel drug resistance. Here we show that these same senescence-mimicking (“senomimetic”) VEGFR TKI effects drive an enhanced immunogenic signaling that, in turn, can alter tumor response to immunotherapy. By using a live cell sorting method to detect β-galactosidase, a commonly used SM, we found that subpopulations of SM-expressing (SM+) tumor cells have heightened IFN signaling and increased expression of IFN-stimulated genes (ISGs). These ISGs increase under the control of the STimulator of the INterferon Gene (STING) signaling pathway, which we found could be directly activated by several VEGFR TKIs. TKI-induced SM+ cells could stimulate or suppress CD8 T-cell activation depending on host–tumor cell contact while tumors grown from SM+ cells were more sensitive to PDL1 inhibition in vivo, suggesting that offsetting immune-suppressive functions of SM+ cells can improve TKI efficacy overall. Our findings may explain why some (but not all) VEGFR TKIs improve outcomes when combined with immunotherapy and suggest that exploiting senomimetic drug side effects may help identify TKIs that uniquely “prime” tumors for enhanced sensitivity to PDL1-targeted agents.
Figure S1: Extended data for Fig 1 - Enriched IFN signaling in SM+ tumor cells after VEGFR TKI treatment. (A) In vivo derivation of 4T1AxR lung metastasis taken from mice after surgical resection of orthotopically implanted 4T1 cells and following Ax treatment (100mg/kg/day). Described in 7. (B) Proliferation analysis of 4T1 cells after treatment with multiple VEGFR TKIs. IC50 values indicated in red. (MTS assay; n = 3-4) (C) In vivo derivation of a Ca-resistant mouse breast tumor cell line EMT6 (EMT6CaR) and vehicle-treated control (EMT6M) taken from lung metastasis of Balb/c mice after orthotopic implantation of EMT6 and following Ca (30mg/kg/day) or vehicle treatment. (D-E) EMT6CaR cells showed increases (compared to EMT6M controls) in D) SM expression (by flow cytometry; n=6) and E) ISG expression (by qRT-PCR; n=3). (F) Proliferation analysis of EMT6M cells after Ca and Ax treatment to choose optimal dosing. IC50 values indicated in red. (MTS assay; n = 3-4) (G-I) SM expression after Ax or Ca treatment in (F) EMT6M, (G) RENCA, and (H) LM2-4 cells (flow cytometry; n=3-6). (J-L) ISG expression after Ca treatment in (I) EMT6M, (J) 4T1, and (K) LM2-4 cells (qRT-PCR; n=3). (M) ISG expression after Ax treatment in EMT6M cells (qRT-PCR; n=3). Parental (P), Axitinib (Ax), Cabozantinib (Ca), Short-term (ST), Vehicle (Veh), Fold Change (FC); Interferon-stimulated genes (ISGs); 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG); Standard deviation (SD); Drug concentration for Ax (0.5µM for F and L; 2µM for G and K) and Ca (2µM for F, G, I and J; 5µM for H and K); #, indicates experiment terminated. Quantitative data is shown as mean ± SD; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Tyrosine kinase inhibitors (TKIs) that block the vascular endothelial growth factor receptors (VEGFRs) not only disrupt tumor angiogenesis but also have many unexpected side effects that impact tumor cells directly. This includes the induction of molecular markers associated with senescence, a form of cellular aging that typically involves growth arrest. We have shown that VEGFR TKIs can hijack these aging programs by transiently inducting senescence markers (SMs) in tumor cells to activate senescence-associated secretory programs that fuel drug resistance. Here we show that these same senescence-mimicking (“senomimetic”) VEGFR TKI effects drive an enhanced immunogenic signaling that, in turn, can alter tumor response to immunotherapy. By using a live cell sorting method to detect β-galactosidase, a commonly used SM, we found that subpopulations of SM-expressing (SM+) tumor cells have heightened IFN signaling and increased expression of IFN-stimulated genes (ISGs). These ISGs increase under the control of the STimulator of the INterferon Gene (STING) signaling pathway, which we found could be directly activated by several VEGFR TKIs. TKI-induced SM+ cells could stimulate or suppress CD8 T-cell activation depending on host–tumor cell contact while tumors grown from SM+ cells were more sensitive to PDL1 inhibition in vivo, suggesting that offsetting immune-suppressive functions of SM+ cells can improve TKI efficacy overall. Our findings may explain why some (but not all) VEGFR TKIs improve outcomes when combined with immunotherapy and suggest that exploiting senomimetic drug side effects may help identify TKIs that uniquely “prime” tumors for enhanced sensitivity to PDL1-targeted agents.
Figure S1: Extended data for Fig 1 - Enriched IFN signaling in SM+ tumor cells after VEGFR TKI treatment. (A) In vivo derivation of 4T1AxR lung metastasis taken from mice after surgical resection of orthotopically implanted 4T1 cells and following Ax treatment (100mg/kg/day). Described in 7. (B) Proliferation analysis of 4T1 cells after treatment with multiple VEGFR TKIs. IC50 values indicated in red. (MTS assay; n = 3-4) (C) In vivo derivation of a Ca-resistant mouse breast tumor cell line EMT6 (EMT6CaR) and vehicle-treated control (EMT6M) taken from lung metastasis of Balb/c mice after orthotopic implantation of EMT6 and following Ca (30mg/kg/day) or vehicle treatment. (D-E) EMT6CaR cells showed increases (compared to EMT6M controls) in D) SM expression (by flow cytometry; n=6) and E) ISG expression (by qRT-PCR; n=3). (F) Proliferation analysis of EMT6M cells after Ca and Ax treatment to choose optimal dosing. IC50 values indicated in red. (MTS assay; n = 3-4) (G-I) SM expression after Ax or Ca treatment in (F) EMT6M, (G) RENCA, and (H) LM2-4 cells (flow cytometry; n=3-6). (J-L) ISG expression after Ca treatment in (I) EMT6M, (J) 4T1, and (K) LM2-4 cells (qRT-PCR; n=3). (M) ISG expression after Ax treatment in EMT6M cells (qRT-PCR; n=3). Parental (P), Axitinib (Ax), Cabozantinib (Ca), Short-term (ST), Vehicle (Veh), Fold Change (FC); Interferon-stimulated genes (ISGs); 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside (C12FDG); Standard deviation (SD); Drug concentration for Ax (0.5µM for F and L; 2µM for G and K) and Ca (2µM for F, G, I and J; 5µM for H and K); #, indicates experiment terminated. Quantitative data is shown as mean ± SD; * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
Supplementary Figure S6: Extended Data from Fig 6 – SM+ tumor growth in vitro and in vivo. (A) Tumor size comparisons between Vehicle and Treated groups for Data shown in Fig 6B (T-tests shown). (B) Schematic for in vitro and in vivo assessment of growth differences between SM+ and SM− FACS-enriched tumor cells from EMT6CaR cells. (C) In vitro proliferation differences between sorted EMT6CaR SM+ and SM- tumor cells evaluated by MTS after 2 days (n=4). (D) In vivo primary tumor growth differences between EMT6CaR SM+ and SM- implanted tumors in Balb/c mice. Left, tumor volume curves (same as in Fig 6E; SM+ and SM- vehicle treated controls for PD-L1 treated groups) and difference in the Gompertz model parameter β (specific growth rate increase) from growth kinetics analysis of primary tumor growth (inset) (n=5). Cabozantinib-resistant (CaR); Senescence-marker (SM); Fluorescent-activated cell sorting (FACS); Fold Change (FC); Standard Deviation (SD); Primary tumor burden was assessed by caliper measurement. See Appendix 4 for details of reduced Gompertz and mixed-effects modeling to evaluate tumor growth kinetics. Quantitative data presented as mean ± SD. * p<0.05; ** p<0.01; Fig S6C represents vehicle control groups from Fig 6E.
Supplementary Figure S5: Extended data from Fig 5 - CD8 T-cell stimulating effects of SM+ cells off-set the immune-suppressive secretory effects. (A-B) Log2FC of %Divided, %GRMB+, or %IFNγ+ gated CD8+ stimulated splenocytes following treatment with (A) CM derived from EMT6CaR tumor cells or (B) co-cultured with EMT6CaR compared to respective parental controls evaluated by flow cytometry (n=3-4). (C-D) %Divided, %GRMB+, or %IFNγ+ gated CD8+ stimulated splenocytes following treatment with (C) CM derived from 4T1AxR tumor cells or (D) co-cultured with 4T1AxR compared to respective parental controls evaluated by flow cytometry (n=3). (E-F) %Divided, %GRMB+, or %IFNγ + gated CD8+ stimulated splenocytes following treatment with (E) CM derived from EMT6CaR tumor cells or (F) co-cultured with EMT6CaR compared to parental controls evaluated by flow cytometry (n=3-4). (G-H) Log2FC of %Divided, %GRMB+, or % IFNγ + gated CD8+ stimulated splenocytes following treatment with (G) CM derived from EMT6CaR SM+ tumor cells or (H) co-cultured with EMT6CaR SM+ compared to SM- controls evaluated by flow cytometry (n=3-4). (I-J) %Divided, %GRMB+, or %IFNγ+ gated CD8+ stimulated splenocytes following treatment with (I) CM derived from 4T1AxR SM+ tumor cells or (J) co-cultured with 4T1AxR SM+ compared to SM- controls evaluated by flow cytometry (n=3-9). (K-L) %Divided, %GRMB+, or %IFNy+ gated CD8+ stimulated splenocytes following treatment with (K) CM derived from EMT6CaR SM+ tumor cells or (L) co-cultured with EMT6CaR SM+ compared to SM- controls evaluated by flow cytometry (n=3-4). Parental (P); Metastatic parental control for EMT6CaR (M); Axitinib-resistant (AxR); Cabozantinib-resistant (CaR); Senescence-marker (SM); Granzyme B (GRMB); Interferon gamma (IFNγ); Conditioned media (CM); Fold Change (FC); Standard Deviation (SD); Normalized (Norm.); Quantitative data shown as mean ± SD. * p<0.05; ** p<0.01; ***n p<0.001; **** p<0.0001.